Early remission status predicts long-term outcomes in patients with Crohn's disease treated with certolizumab pegol
| Autor: | Jason Coarse, Stefan Schreiber, William J. Sandborn, Dermot P.B. McGovern, Marshall Spearman, Gordana Kosutic, Gil Y. Melmed |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
Male medicine.medical_specialty Early remission Gastroenterology 03 medical and health sciences Young Adult 0302 clinical medicine Crohn Disease Internal medicine medicine Long term outcomes Humans In patient 030212 general & internal medicine Certolizumab pegol Young adult Crohn's disease biology business.industry C-reactive protein General Medicine Exploratory analysis Middle Aged medicine.disease Surgery C-Reactive Protein Treatment Outcome biology.protein Certolizumab Pegol Disease Progression 030211 gastroenterology & hepatology Female business Immunosuppressive Agents medicine.drug |
| Zdroj: | Current medical research and opinion. 32(12) |
| ISSN: | 1473-4877 |
| Popis: | In Crohn's disease (CD), rapid response to anti-tumor necrosis factor therapy improves short- and medium-term outcomes, but the relationship between early remission (ER) and long-term remission is unclear.This exploratory analysis of PRECiSE 3 (NCT00160524) assessed whether ER after initiation of certolizumab pegol predicted long-term remission.Patients enrolled in PRECiSE 3 had completed PRECiSE 1 or 2, two randomized placebo-controlled studies for moderate to severe CD, and received open-label certolizumab pegol 400 mg every 4 weeks for a total treatment duration of ≤7.5 years. Time to loss of remission between patients with and without ER (Harvey-Bradshaw Index ≤4 at or before Week 6 of PRECiSE 1 or 2) was compared by log-rank test of Kaplan-Meier estimates.At baseline, patients with (n = 242) and without (n = 148) ER had mean (standard deviation [SD]) durations of CD of 6.8 (6.6) and 7.4 (7.8) years, mean (SD) CD Activity Index scores of 280.3 (53.4) and 311.1 (55.5), with 45.5% and 41.9% of patients having ileocolonic CD, and median C-reactive protein concentrations of 8.0 and 5.0 mg/L, respectively. Median certolizumab pegol plasma concentrations during the first 6 weeks of therapy were similar in both groups. Mean time to loss of remission was significantly longer in patients with versus without ER (2.77 vs. 1.14 years, p 0.0001).In certolizumab pegol-treated patients with CD, ER appears to be an important predictor of long-term clinical remission. Prospective trials are needed to determine whether ER improves other long-term outcomes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|